Free Chat Friday (Every Friday) -- Our live chat room with stock and option alerts! Fridays, starting at 9:30 am, go to: https://goo.gl/O3l5KC use the password: freechatfriday

Sucampo Pharmaceuticals, Inc. Class A
(NASDAQ : SCMP)

( )
SCMP After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson
-0.30%132.640.6%$652.41m
PFEPfizer Inc.
-0.87%32.670.8%$563.97m
MRKMerck & Co., Inc.
-0.58%61.480.6%$492.39m
BMYBristol-Myers Squibb Company
-0.60%56.431.4%$401.07m
ABBVAbbVie, Inc.
0.20%69.992.1%$354.76m
LLYEli Lilly and Company
-0.98%77.041.0%$319.23m
AZNAstraZeneca PLC Sponsored ADR
0.10%29.111.3%$173.16m
GSKGlaxoSmithKline plc Sponsored ADR
-0.72%38.770.2%$116.31m
NVSNovartis AG Sponsored ADR
-0.49%82.780.2%$105.79m
NVONovo Nordisk A/S Sponsored ADR Class B
-0.33%45.190.1%$84.88m
SNYSanofi Sponsored ADR
0.33%48.240.2%$56.48m
LCILannett Company, Inc.
3.31%15.6038.7%$9.62m
SCMPSucampo Pharmaceuticals, Inc. Class A
1.99%10.2514.4%$4.57m
AKTXAkari Therapeutics Plc Sponsored ADR
0.00%4.052.2%$0.21m
EPIXESSA Pharma Inc
0.00%0.340.0%$0.06m

Company Profile

Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in developing, identifying, acquiring and bringing medicines that meet unmet medical needs. It focuses on gastroenterology, ophthalmology, and oncology-related disorders. The company's product pipeline includes AMITIZA for the treatment of chronic idiopathic constipation in adults; irritable bowel syndrome with constipation in adult women; opioid-induced constipation in patients with chronic non-cancer pain; chronic constipation; and pediatric functional constipation. Its product pipeline also consists of Unoprostone Isopropyl, which is in Phase III trial for the treatment of retinitis pigmentosa and in pre-clinical stage for the treatment of geographic atrophy; and Cobiprostone that has completed Phase Ib trial for the treatment of oral mucositis, as well as in Phase II trial for the treatment of non-erosive reflux diseases. Sucampo Pharmaceuticals was founded by Dr. Ryuji Ueno and Dr. Sachiko Kuno on December 5, 1996 and is headquartered in Bethesda, MD.